Table 2.
Univariate and multivariate Cox hazards analysis between clinical features and OS
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age, year | 2.197 (1.177–4.101) | 0.013 | 2.278 (1.172–4.428) | 0.015 |
| Sex | ||||
| Male/female | 0.848 (0.503–1.429) | 0.535 | ||
| TNM stage | ||||
| I/II/III/IV | 3.135 (2.280–4.310) | < 0.001 | ||
| Tumor stage | ||||
| T1/T2/T3/T4 | 1.481 (1.074–2.043) | 0.017 | 1.801 (1.293–2.510) | 0.001 |
| Node stage | ||||
| N0/N1/N2/N3 | 1.317 (1.019–1.701) | 0.035 | ||
| Metastasis | ||||
| No/yes | 4.753 (2.732–8.268) | < 0.001 | 5.164 (2.912–9.157) | < 0.001 |
| Location | ||||
| 1/2/3/4 | 0.958 (0.732–1.254) | 0.757 | ||
| AST, U/L | ||||
| ≤ 22.8/> 22.8 | 1.511 (0.934–2.446) | 0.093 | ||
| ALT, U/L | ||||
| ≤ 30.1/> 30.1 | 0.558 (0.267–1.168) | 0.122 | ||
| LDH, U/L | ||||
| ≤ 168.7/> 168.7 | 2.026 (1.252–3.281) | 0.004 | ||
| GGT, U/L | ||||
| ≤ 26.9/> 26.9 | 3.157 (1.929–5.167) | 0.001 | 2.093 (1.223–3.581) | 0.007 |
| TBA, μmol/L | ||||
| ≤ 5.4/> 5.4 | 2.065 (1.277–3.339) | 0.003 | ||
| ALP, U/L | ||||
| ≤ 80/> 80 | 3.393 (2.093–5.499) | < 0.001 | 2.161 (1.271–3.672) | 0.004 |
| ALB, g/L | ||||
| ≤ 38.8/> 38.8 | 0.541 (0.316–0.837) | 0.007 | ||
| TBIL, μmol/L | ||||
| ≤ 7.3/> 7.3 | 0.623 (0.369–1.053) | 0.077 | ||
| ApoA1, g/L | ||||
| ≤ 1.1/> 1.1 | 0.564 (0.243–1.309) | 0.182 | ||
| ApoB, g/L | ||||
| ≤ 1.1/> 1.1 | 2.056 (1.101–3.841) | 0.024 | ||
| PT, S | ||||
| ≤ 11.9/> 11.9 | 1.464 (0.886–2.419) | 0.137 | ||
| Fbg, g/L | ||||
| ≤ 3.6/> 3.6 | 1.876 (1.052–3.346) | 0.033 | ||